文献速递胸部肿瘤

阿法替尼治疗携带罕见EGFR突变非小细胞肺癌:693例数据库分析

Afatinib for the Treatment of NSCLC Harboring Uncommon EGFR Mutations: A Database of 693 Cases.
PubMed 文献 · J Thorac Oncol · 2020-01-10

该汇总分析评估阿法替尼在693例携带罕见EGFR突变NSCLC患者中的活性,患者来自随机临床试验、同情用药和扩展准入项目、IIIb期试验、非干预试验及病例系列。在315例EGFR TKI初治患者中,阿法替尼对主要罕见突变、复合突变、其他罕见突变及部分外显子20插入突变均显示活性。结论支持阿法替尼在这些情况下使用。

要点

  • 初治患者中主要罕见突变:中位TTF 10.8月,ORR 60.0%。
  • 初治患者中复合突变:中位TTF 14.7月,ORR 77.1%。
  • 初治患者中部分外显子20插入:中位TTF 4.2月,ORR 24.3%。

核心结论

  • 阿法替尼对主要罕见和复合EGFR突变具有临床活性,对其他罕见突变和部分外显子20插入也有广泛活性。
  • 数据支持在这些情况下使用阿法替尼。

研究设计与样本

  • 汇总分析纳入693例携带罕见EGFR突变的NSCLC患者,来自随机临床试验、同情用药和扩展准入项目、IIIb期试验、非干预试验及病例系列或研究。
  • 罕见突变分类为:T790M;外显子20插入;主要罕见突变(G719X、L861Q和S768I,伴或不伴除T790M或外显子20插入外的其他突变);复合突变;其他罕见突变。
  • 关键终点为总缓解率(ORR)、缓解持续时间和治疗失败时间(TTF)。

主要发现

  • 在EGFR TKI初治患者(n=315)中,主要罕见突变:中位TTF 10.8月(95%CI 8.1-16.6),ORR 60.0%。
  • 复合突变:中位TTF 14.7月(95%CI 6.8-18.5),ORR 77.1%。
  • 其他罕见突变:中位TTF 4.5月(95%CI 2.9-9.7),ORR 65.2%。
  • 部分外显子20插入:中位TTF 4.2月(95%CI 2.8-5.3),ORR 24.3%。
  • 主要罕见突变、复合突变、其他罕见突变和部分外显子20插入的中位缓解持续时间分别为17.1、16.6、9.0和11.9个月。

关键数值与推荐

  • 主要罕见突变:中位TTF 10.8月(95%CI 8.1-16.6),ORR 60.0%,中位缓解持续时间17.1月。
  • 复合突变:中位TTF 14.7月(95%CI 6.8-18.5),ORR 77.1%,中位缓解持续时间16.6月。
  • 其他罕见突变:中位TTF 4.5月(95%CI 2.9-9.7),ORR 65.2%,中位缓解持续时间9.0月。
  • 部分外显子20插入:中位TTF 4.2月(95%CI 2.8-5.3),ORR 24.3%,中位缓解持续时间11.9月。

临床怎么用

  • 对于携带主要罕见或复合EGFR突变的NSCLC患者,可考虑使用阿法替尼。
  • 对于携带其他罕见突变或部分外显子20插入的患者,阿法替尼也有一定活性,可作为治疗选择。
  • 已生成可按个体基因型检索结局的可搜索数据库,有助于临床决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Limited clinical data are available regarding the efficacy of EGFR tyrosine kinase inhibitors (EGFR TKIs) in patients with NSCLC harboring uncommon EGFR mutations. This pooled analysis assessed the activity of afatinib in 693 patients with tumors harboring uncommon EGFR mutations treated in randomized clinical trials, compassionate-use and expanded-access programs, phase IIIb trials, noninterventional trials, and case series or studies. METHODS: Patients had uncommon EGFR mutations, which were categorized as follows: (1) T790M; (2) exon 20 insertions; (3) "major" uncommon mutations (G719X, L861Q, and S768I, with or without any other mutation except T790M or an exon 20 insertion); (4) compound mutations; and (5) other uncommon mutations. Key end points were overall response rate (ORR), duration of response, and time to treatment failure (TTF). RESULTS: In EGFR TKI-naive patients (n = 315), afatinib demonstrated activity against major uncommon mutations (median TTF = 10.8 mo; 95% confidence interval [CI]: 8.1-16.6; ORR = 60.0%), compound mutations (median TTF = 14.7 mo; 95% CI: 6.8-18.5; ORR = 77.1%), other uncommon mutations (median TTF = 4.5 mo; 95% CI: 2.9-9.7; ORR = 65.2%), and some exon 20 insertions (median TTF = 4.2 mo; 95% CI: 2.8-5.3; ORR = 24.3%). The median duration of response for major uncommon mutations, compound mutations, other uncommon mutations, and some exon 20 insertions was 17.1, 16.6, 9.0, and 11.9 months, respectively. Activity of afatinib was also observed in EGFR TKI-pretreated patients (n = 378). A searchable database of these outcomes by individual genotype was generated. CONCLUSIONS: Afatinib has clinical activity in NSCLC against major uncommon and compound EGFR mutations. It also has broad activity against other uncommon EGFR mutations and some exon 20 insertions. The data support the use of afatinib in these settings.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Yang JC, Schuler M, Popat S, et al. Afatinib for the Treatment of NSCLC Harboring Uncommon EGFR Mutations: A Database of 693 Cases. J Thorac Oncol. 2020. PMID: 31931137. doi:10.1016/j.jtho.2019.12.126

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。